Polygenic architecture informs potential vulnerability to drug-induced liver injury

Journal: Nature Medicine

Published: 2020-09-07

DOI: 10.1038/s41591-020-1023-0

Affiliations: 13

Authors: 14

Go to article
Institutions Share
Takeda-CiRA Joint Program (T-CiRA), Japan 0.25
Takeda Pharmaceutical Shonan Institute, Japan 0.24
Graduate School of Medical Life Science, YCU, Japan 0.12
Department of Genetics and Genomic Sciences, ISMMS, United States of America (USA) 0.07
NIHR Nottingham Respiratory Biomedical Research Centre (BRU), United Kingdom (UK) 0.07
Faculty of Medical Sciences, Newcastle University, United Kingdom (UK) 0.07
UNC Eshelman School of Pharmacy, United States of America (USA) 0.07
Takeda Cambridge, Massachusetts, United States of America (USA) 0.07
Institute of Research, TMDU, Japan 0.01
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA) 0.01
UC Center for Stem Cell and Organoid Medicine (CuSTOM), United States of America (USA) 0.01
UC Department of Pediatrics, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER